Gene therapy returns to centre stage
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an excellent safety record. They provide evidence for the long-sought promise of gene therapy to deliver 'cures' for some otherwise terminal or severely disabling conditions. Behind these advances lie improved vector designs that enable the safe delivery of therapeutic genes to specific cells. Technologies for editing genes and correcting inherited mutations, the engagement of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight cancer are also contributing to the revitalization of gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation (allo-HSCT) can provide a one-time and life-long cure for patients with serious genetic hematological diseases such as primary immunodeficiencies20 and hemoglobinopathies21,22, if a suitable immunologically matched donor can be found23.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [23]
In the citing paper
“Although insertional mutagenesis risk has been reduced by improved vector design19, the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) at 3–5.5 years post-transplantation in 2 of 47 patients who had undergone GT for SCD20–23 has generated renewed concerns.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [19]
In the citing paper
“Gene therapy with autologous hematopoietic stem cells has been investigated as an alternative to allogeneic hematopoietic stem-cell transplantation.11–13”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [12]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Research works printed but not linked: 1
- Baxter. Baxalta reports continued progress on phase 1/2 clinical trial of BAX335, investigational gene therapy treatment for hemophilia B. Baxter http://www.baxter.com/news-media/newsroom/press-releases/2015/06_24_15_bax335.page (2015).
Cited by
Items 401–500 of 1,000
Zhou, Y., Yu, M., Tie, C., Deng, Y., Wang, J., Yi, Y., Zhang, F., Huang, C., Zheng, H., Mei, L., et al. (2021) · Research · doi:10.34133/2021/9760398 · Cited by 34
Recent development of gene therapy for pancreatic cancer using non-viral nanovectors
Liu, Y., Wu, W., Wang, Y., Han, S., Yuan, Y., Huang, J., Shuai, X., & Peng, Z. M. (2021) · Biomaterials Science · doi:10.1039/d1bm00748c · Cited by 36
Vinyl Polymer-based technologies towards the efficient delivery of chemotherapeutic drugs
Pereira, P., Serra, A. C., & Coelho, J. F. J. (2021) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2021.101432 · Cited by 34
Ding, N., Luo, G., Li, H., Xing, C., Gao, Y., Xi, W., Wu, W., Wang, D., Zheng, L., Kang, Y., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301243 · Cited by 37
Tan, S. C. L., He, Z., Wang, G., Yu, Y., & Yang, L. (2023) · Molecules · doi:10.3390/molecules28145531 · Cited by 35
“Apart from drug delivery, nanoparticles can also be used as a carrier for gene delivery to achieve beneficial therapeutic outcomes by counteracting or repairing defective genes in the cells that cause diseases [186].”
BackgroundCell-Targeting Cationic Gene Delivery System Based on a Modular Design Rationale
Liu, J., Xu, L., Jin, Y., Qi, C., Li, Q., Zhang, Y., Jiang, X., Wang, G., Wang, Z., & Wang, L. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b04462 · Cited by 32
Epilepsy and optogenetics: can seizures be controlled by light?
Tønnesen, J., & Kokaia, M. (2017) · Clinical Science · doi:10.1042/cs20160492 · Cited by 40
Guo, J., Mattos, B. D., Tardy, B. L., Moody, V. M., Xiao, G., Ejima, H., Cui, J., Liang, K., & Richardson, J. J. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180706111909 · Cited by 32
Peterson, S. J., Rubinstein, R., Faroqui, M., Raza, A. S., Boumaza, I., Zhang, Y., Stec, D. E., & Abraham, N. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102514 · Cited by 34
“Gene transfer has been used for years in oncology [26,27] and only recently appreciated as a treatment of obesity [28,29].”
BackgroundWang, Y., Shi, J., Zhou, Y., Liu, T., Fang-Ling, Z. H. A. N., Zhang, K. N., & Liu, N. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4833 · Cited by 37
“Identifying specific gene mutations and alterations in expression in tumor tissues have been the main focus of cancer research, and have led to developments in immunotherapy (11-13).”
BackgroundMarcó, S., Haurigot, V., & Bosch, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.217 · Cited by 41
“61,62 63–67 This overview will focus on in vivo gene therapies for MPSIII.”
Li, Y., Liu, L., Ji, W., Peng, H., Zhao, R., & Zhang, X. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101006 · Cited by 36
Rong, N., Zhou, H., Liu, R., Wang, Y., & Fan, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.014 · Cited by 31
Tomás, R. M. F., Martyn, B. T., Bailey, T. L., & Gibson, M. I. (2018) · ACS Macro Letters · doi:10.1021/acsmacrolett.8b00675 · Cited by 34
Human genome editing in the clinic: new challenges in regulatory benefit-risk assessment
Abou-El-Enein, M., Cathomen, T., Ivics, Z., June, C. H., Renner, M., Schneider, C. K., & Bauer, G. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.09.007 · Cited by 31
“The transferred genes usually complement or replace the function of the dysfunctional genes, thereby correcting the phenotype of the targeted cells (Naldini, 2015).”
BackgroundMethodNew Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K+/H+ Exchange
Rangasamy, L., Chelvam, V., Kanduluru, A. K., Srinivasarao, M., Bandara, N. A., You, F., Orellana, E. A., Kasinski, A. L., & Low, P. S. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00714 · Cited by 31
Mesenchymal stem cells as carrier of the therapeutic agent in the gene therapy of blood disorders
Shomali, N., Gharibi, T., Vahedi, G., Mohammed, R. N., Mohammadi, H., Salimifard, S., & Marofi, F. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29324 · Cited by 30
“Direct injection of gene therapy agents into tumor tissue or intravenous injection or through inhalation (Naldini, 2015).”
BackgroundTozzo, P., Zullo, S., & Caenazzo, L. (2020) · Brain Sciences · doi:10.3390/brainsci10070421 · Cited by 33
Zhou, L., Li, Y., Liang, Q., Liu, J., & Liu, Y. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2044485 · Cited by 34
Yang, R., Chai, R., Pan, J.-Y., Pan, J., Xia, P.-H., Wang, Y.-K., Chen, Y., Li, Y., Wu, J., & Chen, G. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.346463 · Cited by 33
“Recently, some AAV-mediated clinical gene therapeutic approaches have been verified, such as GlaxoSmithKline’s severe combined immunodeficiency therapy (Naldini, 2015).”
BackgroundHe, X., Liu, B., Peng, Y., Zhuo, R., & Cheng, S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b17481 · Cited by 32
Smith, D. K. (2018) · Chemical Communications · doi:10.1039/c8cc01753k · Cited by 33
Fang, C.-C., Wu, C.-F., Liao, Y., Huang, S.-F. K., Chen, M., & Chen, Y. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-30800-3 · Cited by 30
Jiang, H., Hu, X., Mosel, S., Knauer, S. K., Hirschhäuser, C., & Schmuck, C. (2019) · ChemBioChem · doi:10.1002/cbic.201800728 · Cited by 30
Nucleic Acid Immunotherapeutics for Cancer
Shen, T., Zhang, Y., Zhou, S., Lin, S., Zhang, X., & Zhu, G. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00101 · Cited by 33
WFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia
Cantore, A., & Naldini, L. (2020) · Haemophilia · doi:10.1111/hae.14056 · Cited by 34
Self-citationFacile Synthesis of N-Doped Graphene Quantum Dots as Novel Transfection Agents for mRNA and pDNA
Ahn, M., Song, J., & Hong, B. H. (2021) · Nanomaterials · doi:10.3390/nano11112816 · Cited by 31
Gothwal, A., Lamptey, R. N. L., & Singh, J. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00031 · Cited by 31
Guen, V. L., Judor, J., Boeffard, F., Gauttier, V., Ferry, N., Soulillou, J., Brouard, S., & Conchon, S. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.019 · Cited by 35
Cross-linked polymers with fluorinated bridges for efficient gene delivery
Xiao, Y., Zhang, J., Liu, Y., Huang, Z., Wang, B., Zhang, Y., & Yu, X. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb02158e · Cited by 30
Astilbin ameliorates pulmonary fibrosis via blockade of Hedgehog signaling pathway
Zhang, J., Liu, H., Song, C., Zhang, J., Wang, Y., Lv, C., & Song, X. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.03.006 · Cited by 31
Recent progress of iron-based nanomaterials in gene delivery and tumor gene therapy
Gong, Y., Hu, X., Chen, M., & Wang, J. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02550-0 · Cited by 35
“In addition, since gene expression is strictly controlled by cells to maintain the homeostasis of normal human tissues and tumor micro-environment, the potential side effects of exogenous therapeutic genes cannot be ignored [11].”
BackgroundGene and Base Editing as a Therapeutic Option for Cystic Fibrosis—Learning from Other Diseases
Mention, K., Santos, L., & Harrison, P. T. (2019) · Genes · doi:10.3390/genes10050387 · Cited by 34
“In contrast, both in vivo and ex vivo gene therapy approaches have been very successful in a wide range of other diseases over the same time frame [5].”
BackgroundAnti-ageing gene therapy: Not so far away?
Vaiserman, A. M., FALCO, E. D., Koliada, A. K., Maslova, O., & Balistreri, C. R. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100977 · Cited by 34
Transfecting tissue models with CRISPR/Cas9 plasmid DNA using peptide dendrimers
Zamolo, S., Darbre, T., & Reymond, J. (2020) · Chemical Communications · doi:10.1039/d0cc04750c · Cited by 31
Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy
Johnson, P. C., Jacobson, C. A., Yi, A., Saucier, A., Dhawale, T. M., Nelson, A. M., Lavoie, M. W., Reynolds, M. J., Topping, C. E. W., Frigault, M. J., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7678 · Cited by 34
Wang, W., Zhang, Y., Dettinger, P., Reimann, A., Kull, T., Loeffler, D., Manz, M. G., Lengerke, C., & Schroeder, T. (2021) · Blood · doi:10.1182/blood.2020008386 · Cited by 33
Liu, H., Wu, X., Gan, C., Wang, L., Wang, G., Lin, Y., Liu, Z., Wei, W., Su, X., Zhang, Q., et al. (2021) · Cell Proliferation · doi:10.1111/cpr.13081 · Cited by 30
Progress in Nanocarriers Codelivery System to Enhance the Anticancer Effect of Photodynamic Therapy
Yang, Y., Lin, K., & Li, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111951 · Cited by 32
Recent advances in aptamer-based therapeutic strategies for targeting cancer stem cells
Liu, B., Liu, J., Hu, X., Xiang, W., Hou, W., Li, C., Wang, J., Yao, K., Tang, J. H., Long, Z., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100605 · Cited by 37
“Gene therapy emerged in recent years and displayed great potential to treat cancers, especially those that are resistant to conventional therapy [55,56].”
BackgroundEngineering polyphenol-based carriers for nucleic acid delivery
Shui, M., Chen, Z., Chen, Y., Yuan, Q., Li, H., Vong, C. T., Farag, M. A., & Wang, S. (2023) · Theranostics · doi:10.7150/thno.81604 · Cited by 31
Overview on Research and Clinical Applications of Optogenetics
Towne, C. L., & Thompson, K. R. (2016) · Current Protocols in Pharmacology · doi:10.1002/cpph.13 · Cited by 31
“Fortunately, AAV gene delivery methods predate optogenetics and advanced techniques routinely achieve precise targeting of large volumes of parenchyma in non-human primates and humans (see review by Nash and Gordon, 2016).”
BackgroundZhao, X., Wang, J., Song, Y., & Chen, X. (2018) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2018.1449853 · Cited by 30
Bastani, S., Staal, F. J. T., & Canté-Barrett, K. (2023) · Stem Cell Investigation · doi:10.21037/sci-2023-016 · Cited by 35
“Of course, HSC function should be maintained during the ex vivo expansion of HSCs for genetic manipulation (32).”
CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon
Wu, D., Xu-Monette, Z. Y., Zhou, J., Yang, K., Wang, X., Fan, Y., & Young, K. H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1613878 · Cited by 50
“Traditional CAR T cells use lentiviral or gamma-retroviral vectors for permanent genetic modi fi cation, which poses risks of genotoxicity and regulatory challenges, and may also result in the lifelong persistence of CAR T cells (162, 163).”
Maiti, B., Kamra, M., Karande, A. A., & Bhattacharya, S. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02835k · Cited by 28
Characterization of Extracellular Vesicles Secreted in Lentiviral Producing HEK293SF Cell Cultures
Minh, A. D., Star, A. T., Stupak, J., Fulton, K. M., Haqqani, A. S., Gélinas, J., Li, J., Twine, S. M., & Kamen, A. (2021) · Viruses · doi:10.3390/v13050797 · Cited by 36
“In the past decade, gene and cell therapies have become increasingly popular tools to treat diseases such as genetic disorders, cancer, cardiovascular disease, as well as a wide spectrum of orphan diseases [1].”
BackgroundBranch Unit Distribution Matters for Gene Delivery
Li, Y., He, Z., Wang, X., Li, Z., Johnson, M., Foley, R., Sigen, A., Lyu, J., & Wang, W. (2023) · ACS Macro Letters · doi:10.1021/acsmacrolett.3c00152 · Cited by 29
Madrigal, J. L., Shams, S., Stilhano, R. S., & Silva, E. A. (2018) · Biomaterials Science · doi:10.1039/c8bm01218k · Cited by 29
HMGA2 promotes cancer metastasis by regulating epithelial–mesenchymal transition
Ma, Q., Ye, S., Liu, H., Zhao, Y., Mao, Y., & Zhang, W. Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1320887 · Cited by 41
Efficient delivery of DNA into bovine preimplantation embryos by multiwall carbon nanotubes
Munk, M., Ladeira, L. O., de Carvalho, B. C., Camargo, L. S. A., Raposo, N. R. B., Serapião, R. V., Quintão, C. C. R., Silva, S. R., Soares, J. S., Jório, A., et al. (2016) · Scientific Reports · doi:10.1038/srep33588 · Cited by 27
Tarvirdipour, S., Schoenenberger, C., Benenson, Y., & Palivan, C. G. (2020) · Soft Matter · doi:10.1039/c9sm01990a · Cited by 27
Haughan, J. E., Jiang, Z., Stefanovski, D., Moss, K. L., Ortved, K. F., & Robinson, M. A. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2785 · Cited by 29
Applications of tetrahedral DNA nanostructures in wound repair and tissue regeneration
Dou, Y., Cui, W., Yang, X., Lin, Y., Ma, X., & Cai, X. (2022) · Burns & Trauma · doi:10.1093/burnst/tkac006 · Cited by 29
“This review summarizes the progress of TDN research in wound repair and regeneration to promote further research in the field of tissue engineering [49,50].”
Nanoparticle-mediated conversion of primary human astrocytes into neurons and oligodendrocytes
Li, X., Kozielski, K., Cheng, Y., Liu, H., Zamboni, C. G., Green, J. J., & Mao, H. (2016) · Biomaterials Science · doi:10.1039/c6bm00140h · Cited by 28
Novel guanidinylated bioresponsive poly(amidoamine)s designed for short hairpin RNA delivery
Yu, J., Zhang, J., Xing, H., Sun, Y., Yang, Z. L., Yang, T., Cai, C., Zhao, X., Yang, L., & Ding, P. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s115773 · Cited by 27
Wu, J., Xue, H. Y., Lyu, Z., Li, Z., Qu, Y., Xu, Y., Wang, L., Yu, Q., & Chen, H. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b06201 · Cited by 28
Bogacheva, M. S., Egorova, A., Slita, A., Maretina, M. A., Баранов, В. С., & Kiselev, A. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.001 · Cited by 27
Dendrimer-based nanoparticles in cancer chemotherapy and gene therapy
Jiang, L., Zhou, S., Zhang, X., Wu, W., & Jiang, X. (2018) · Science China Materials · doi:10.1007/s40843-018-9242-3 · Cited by 27
Lin, M.-C., Wang, M., Chou, M.-C., Chao, C., Fang, C., Chen, P., Chang, D., & Shen, C. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0083-0 · Cited by 29
Sun, T., Li, H., Bai, Y., Bai, M., Gao, F., Yu, J., Wu, R., Du, L., & Li, F. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01655-1 · Cited by 36
COLEC12 regulates apoptosis of osteosarcoma through Toll‐like receptor 4–activated inflammation
Li, G., Deng, J., Qi, Y., Liu, R., & Liu, Z. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23469 · Cited by 29
Pizzuto, M., Gangloff, M., Scherman, D., Gay, N. J., Escriou, V., Ruysschaert, J., & Lonez, C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.029 · Cited by 26
“Contents lists available at ScienceDirect Journal of Controlled Release j ourna l homepage: www.e lsev ie r .com/ locate / jconre l Toll-like receptor 2 promiscuity is responsible for the immunostimulatory activity of nucleic acid nanocarriers Malvina Pizzuto a,⁎,1, Monique Gangloff b,⁎,1, Daniel Scherman c,d,e,f, Nic…”
BackgroundTherapeutic genome engineering via CRISPR ‐Cas systems
Moreno, A. M., & Mali, P. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1380 · Cited by 30
“In a recent review, some relevant genetic therapy clinical trials were highlighted in which lentiviruses were safely utilized to treat Wiskot-Aldrich syndrome, β-Thalassaemia, and various T-cell immunotherapy for cancer.(70) Additionally, some in vivo studies utilizing CRISPR-Cas systems have also demonstrated robust…”
BackgroundTherapeutic applications of group I intron‐based trans‐splicing ribozymes
Lee, C. H., Han, S. R., & Lee, S. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1466 · Cited by 33
“…genes to cells lacking the endogenous genes or harboring their defective copies or using molecules such as siRNA, antisense oligonucleotide (ASO), or ribozymes to suppress the expression of disease-associated gene products based on the type of disease (Collins & Thrasher, 2015; Naldini, 2015).”
BackgroundIn vivo methods for acute modulation of gene expression in the central nervous system
Cwetsch, A. W., Pinto, B., Savardi, A., & Cancedda, L. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.04.008 · Cited by 30
“Since then, due to the therapeutic benefits and the safety found in subsequent clinical trials, gene therapy has become a possible option for clinical intervention in some otherwise terminal or severely disabling conditions (Naldini, 2015).”
Promise of gene therapy to treat sickle cell disease
Romero, Z. G., DeWitt, M. A., & Walters, M. C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1536119 · Cited by 30
Hou, X., Shou, C., He, M., Xu, J., Cheng, Y., Yuan, Z., Lan, M., Zhao, Y., Yang, Y. A., Chen, X., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.010 · Cited by 26
Ravula, V., Lo, Y.-L., Wu, Y., Chang, C., Patri, S. V., & Wang, L. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112189 · Cited by 26
Zhou, J. J., Sun, L., Wang, L., Liu, Y., Li, J., Li, J., Li, J., & Yang, H. (2019) · Angewandte Chemie · doi:10.1002/ange.201813665 · Cited by 26
Wang, L., Li, Z., Wang, Y., Gao, M., He, T., Zhan, Y., & Li, Z. (2023) · Nanoscale · doi:10.1039/d3nr01723k · Cited by 26
Duan, D. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2016.001 · Cited by 31
“A new generation of retro/lentiviral vectors has been developed to minimize this safety concern.(4)”
The emerging role of viral vectors as vehicles for DMD gene editing
Maggio, I., Chen, X., & Gonçalves, M. A. F. V. (2016) · Genome Medicine · doi:10.1186/s13073-016-0316-x · Cited by 28
“Similarly to their effective contribution to “classic” gene replacement therapies [33], viral vectors are expected to become instrumental tools for investigating and developing therapeutic in vivo and ex vivo geneediting approaches (for a recent review on the adaptation and testing of viral vector systems for genome e…”
Morys, S., Levačić, A. K., Urnauer, S., Kempter, S., Kern, S., Rädler, J. O., Spitzweg, C., Lächelt, U., & Wagner, E. (2017) · Polymers · doi:10.3390/polym9040142 · Cited by 32
A Vesicular Stomatitis Virus‐Inspired DNA Nanocomplex for Ovarian Cancer Therapy
Zhao, W., Yang, Y., Song, L., Kang, T., Du, T., Wu, Y., Xiong, M., Luo, L., Long, J., Men, K., et al. (2017) · Advanced Science · doi:10.1002/advs.201700263 · Cited by 25
Li, Y., Kong, Q., Yue, J., Gou, X., Xu, M., & Wu, X. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0293-z · Cited by 26
Nyström, N. N., Hamilton, A. M., Xia, W., Liu, S., Scholl, T. J., & Ronald, J. A. (2019) · Investigative Radiology · doi:10.1097/rli.0000000000000542 · Cited by 28
Wang, J., Zhu, L., Chen, X., Huang, R., Wang, S., & Dong, P. (2019) · Stem Cells and Development · doi:10.1089/scd.2018.0252 · Cited by 26
“…to the intrinsic biological capabilities of stem cells, such as homing, trafficking potential, and regenerative capacity, they can serve as vehicles for targeted gene delivery; this potential provides opportunities for gene therapy to overcome a large number of uncon-quered medical challenges [6].”
Synthetic biology and occupational risk
Howard, J., Murashov, V. V., & Schulte, P. A. (2017) · Journal of Occupational and Environmental Hygiene · doi:10.1080/15459624.2016.1237031 · Cited by 26
Sun, J., Lian, M., Ma, H., Wang, R., Ma, Z., Wang, H., Zhai, J., Meng, L., Ling, F., Bai, Y., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8307 · Cited by 30
“In recent years, cancer immunotherapy has gradually become a subject undergoing intense study in cancer research and has achieved satisfactory therapeutic efficacy in the clinical treatment of cancers (5).”
Gene Therapies for Polyglutamine Diseases
Matos, C. A., Carmona, V., Vijayakumar, U. G., Lopes, S., Albuquerque, P., Conceição, M., Nobre, R. J., Nóbrega, C., & de Almeida, L. P. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-71779-1_20 · Cited by 32
Blockade of integrin α3 attenuates human pancreatic cancer via inhibition of EGFR signalling
Lee, J., Lee, J., Choi, C., & Kim, J. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-39628-x · Cited by 26
Safe engineering of cancer-associated fibroblasts enhances checkpoint blockade immunotherapy
Geng, S., Xiang, T., Zhang, Y., Guo, P., Zhang, H., Zhang, Z., Gu, M., Zhang, K., Song, H., Shi, J., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.041 · Cited by 27
Electroactive nanoinjection platform for intracellular delivery and gene silencing
Shokouhi, A., Chen, Y., Yoh, H. Z., Murayama, T., Suu, K., Morikawa, Y., Brenker, J., Alan, T., Voelcker, N. H., & Elnathan, R. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02056-1 · Cited by 33
“…(e.g., gene-editing tools [17–19], nucleic acids [20–23], proteins [24–26], and nanoparticles [27–31]) is set to broaden the modality and cellular targets of therapeutic delivery for in vivo [32, 33] and ex vivo[34–37] gene therapy, CAR-T cell therapy [10, 38–43], and stem cell therapy [37, 44–47].”
BackgroundJabbari, A., Sameiyan, E., Yaghoobi, E., Ramezani, M., Alibolandi, M., Abnous, K., & Taghdisi, S. M. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123448 · Cited by 31
Applications of CRISPR/Cas9 for Gene Editing in Hereditary Movement Disorders
Im, W., Moon, J., & Kim, M. (2016) · Journal of Movement Disorders · doi:10.14802/jmd.16029 · Cited by 32
Microfluidic generation of alginate microgels for the controlled delivery of lentivectors
Madrigal, J. L., Stilhano, R. S., Siltanen, C. A., Tanaka, K., Rezvani, S. N., Morgan, R. P., Revzin, A., Han, S. W., & Silva, E. A. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb02150f · Cited by 25
Grisch‐Chan, H. M., Schlegel, A. A., Scherer, T., Allegri, G., Heidelberger, R., Tsikrika, P., Schmeer, M., Schleef, M., Harding, C. O., Häberle, J., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.013 · Cited by 27
Rare Diseases: Drug Discovery and Informatics Resource
Zhao, M., & Wei, D. (2017) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-017-0270-3 · Cited by 27
Dharmalingam, P., Rachamalla, H. K., Lohchania, B., Bandlamudi, B. P., Thangavel, S., Mohankumar, K. M., Banerjee, R., Chaudhuri, A., Voshavar, C., & Marepally, S. K. (2017) · ACS Omega · doi:10.1021/acsomega.7b00935 · Cited by 25
Wang, X., Wang, J., Geng, Y., Wang, J., Zhang, X., Yang, S.-S., Jiang, W. Z., & Liu, W. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.108 · Cited by 27
Poletti, V., Urbinati, F., Charrier, S., Corre, G., Hollis, R. P., Fernandez, B. C., Martin, S., Rothe, M., Schambach, A., Kohn, D. B., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.014 · Cited by 27
“LV-transduced HSPCs have been used in clinical trials of gene therapy for immunodeficiencies and lysosomal storage disorders, providing strong evidence of safety and long-term efficacy in most cases.(5) Gene therapy for SCD faces additional challenges: although the size of the gene expression cassette has been reduced…”
MethodCurrent Status of Gene Therapy Research in Polyglutamine Spinocerebellar Ataxias
Afonso‐Reis, R., Afonso, I. T., & Nóbrega, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084249 · Cited by 26
Synthetic macromolecular switches for precision control of therapeutic cell functions
Teixeira, A. P., & Fussenegger, M. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00235-9 · Cited by 34
“Autologous haematopoietic stem cell (HSC) transplantation, following ex vivo gene transfer or correction, has been clinically approved for several diseases, including β-thalassaemia and X-linked severe combined immunodeficiency 121 .”
Advances in Cancer Treatment Through Nanotheranostics and Emerging Therapies
Akpe, V., & Cock, I. E. (2025) · Journal of Nanotheranostics · doi:10.3390/jnt6040029 · Cited by 31
“CRISPR-Cas9 enables precise DNA modifications, offering new avenues to investigate tumor mutational burden and mechanisms of immune evasion that influence cancer immunotherapy response [237–239].”
RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers
Magalhães, M., Alvarez‐Lorenzo, C., Concheiro, Á., Figueiras, A., Paiva‐Santos, A. C., & Veiga, F. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1517744 · Cited by 23
Hematopoietic Stem Cell Gene Therapy for Brain Metastases Using Myeloid Cell–Specific Gene Promoters
Andreou, T., Rippaus, N., Wronski, K., Williams, J. M., Taggart, D., Cherqui, S., Sunderland, A., Kartika, Y. D., Egnuni, T., Brownlie, R. J., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz181 · Cited by 27
Dai, Y., Zhao, X., Li, F., Yuan, Y., Yan, D., Cao, H., Huang, X., Hu, Z., Ma, D., & Gao, Q. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.206 · Cited by 25
“14,15 Among various vectors, adenoviruses (Ads) have efficacy, safety, and manufacturing characteristics that make them attractive as oncolytic virus candidates and suitable gene delivery vectors.”
B4GalT1 Regulates Apoptosis and Autophagy of Glioblastoma In Vitro and In Vivo
Wang, P., Li, X., & Xie, Y. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820980104 · Cited by 25
“Gene therapy is the most promising treatment and has long fascinated scientists, clinicians, and the public because of its potential to treat cancer at its genetic roots.(22) Due to the bad outcomes of glioblastoma, treatment will be guided by searching for genes which may play a regulatory role in glioblastoma.”
BackgroundBiomimetic gene editing system for precise tumor cell reprogramming and augmented tumor therapy
Qiao, L., Gao, M., Yi, X., Peng, H., Zhang, R., Yao, W., Sun, G., & He, X. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.020 · Cited by 27
Metadata
- Authors
- Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Naldini, Luigi
- ORCID
- Naldini, Luigi
- Venue
- Nature
- Published
- 2015-10
- Volume
- 526
- Issue
- 7573
- Pages
- 351-360
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1902159756
- Semantic Scholar
- 334eb76dbe52abdfcdb4be9aa772d017378a95d3
- Cited by
- 1,184
- References
- 124
- Citations by year
- 2026: 67 · 2025: 77 · 2024: 59 · 2023: 75 · 2022: 76 · 2021: 99 · 2020: 141 · 2019: 132 · 2018: 182 · 2017: 158 · 2016: 109 · 2015: 7
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon
- Ministero della Salute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- gene therapy, clinical trials, gene therapy vectors, genome editing, inherited mutations, stem cell therapy, tissue regeneration, cancer immunotherapy, gene therapy safety
- MeSH terms
- Clinical Trials as Topic, Hematopoietic Stem Cells, Humans, Immunotherapy, Liver, Neoplasms, Organ Specificity, T-Lymphocytes, Genetic Therapy, Gene Targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.